Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.23 is 13% above its 3-year average of -2.57, around the middle of its 3-year range (-4.07–-0.90).
16.01% above its 12-month average of -2.66.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.58.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.23
EARNINGS PER SHARE (EPS) AVG TTM
-2.66
EARNINGS PER SHARE (EPS) AVG 3Y
-2.57
EARNINGS PER SHARE (EPS) AVG 5Y
-2.57
EARNINGS PER SHARE (EPS) AVG 10Y
-1.26
EARNINGS PER SHARE (EPS) AVG 15Y
-0.64
EARNINGS PER SHARE (EPS) AVG 20Y
-0.82
CURRENT VS TTM AVG
+16.01%
CURRENT VS 3Y AVG
+13.23%
CURRENT VS 5Y AVG
+13.23%
CURRENT VS 10Y AVG
-76.52%
CURRENT VS 15Y AVG
-248.44%
CURRENT VS 20Y AVG
-171.25%
CAMP4 Therapeutics Corporation
Market Cap
$252.90M
Earnings Per Share (EPS)
-2.23
TTM Avg
-2.66
3Y Avg
-2.57
5Y Avg
-2.57
Market Cap
$249.82M
Earnings Per Share (EPS)
-1.54
TTM Avg
-1.32
3Y Avg
-0.98
5Y Avg
-0.74
Market Cap
$248.92M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.79
3Y Avg
-0.77
5Y Avg
-0.98
Market Cap
$251.06M
Earnings Per Share (EPS)
-0.39
TTM Avg
-0.86
3Y Avg
-1.43
5Y Avg
-1.56
Market Cap
$246.96M
Earnings Per Share (EPS)
-0.43
TTM Avg
-0.62
3Y Avg
-0.66
5Y Avg
-0.59
Market Cap
$244.56M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.09
3Y Avg
-1.28
5Y Avg
-1.70
Market Cap
$241.70M
Earnings Per Share (EPS)
-0.11
TTM Avg
-0.18
3Y Avg
-0.30
5Y Avg
-0.87
Market Cap
$261.48M
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.90
3Y Avg
-0.84
5Y Avg
-0.86
Market Cap
$240.76M
Earnings Per Share (EPS)
-0.28
TTM Avg
-0.24
3Y Avg
-0.42
5Y Avg
-0.45
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CAMP4 Therapeutics Corporation (CAMP) | $252.90M | -2.23 | -2.66 | -2.57 | -2.57 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.82M | -1.54 | -1.32 | -0.98 | -0.74 |
| InflaRx N.V. (IFRX)vs › | $248.92M | -0.57 | -0.79 | -0.77 | -0.98 |
| Invivyd, Inc. (IVVD)vs › | $251.06M | -0.39 | -0.86 | -1.43 | -1.56 |
| Galectin Therapeutics Inc. (GALT)vs › | $246.96M | -0.43 | -0.62 | -0.66 | -0.59 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.56M | N/A | -1.09 | -1.28 | -1.70 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $241.70M | -0.11 | -0.18 | -0.30 | -0.87 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.48M | -0.99 | -0.90 | -0.84 | -0.86 |
| High Tide Inc. (HITI)vs › | $240.76M | -0.28 | -0.24 | -0.42 | -0.45 |
| BioAge Labs Inc. (BIOA)vs › | $242.46M | -2.38 | -2.11 | -1.81 | -1.81 |
Trailing EPS (TTM)
$-2.23
Forward EPS (Est.)
$-1.14
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.65 |
| 2024-12-31 | -2.66 |
| 2023-11-30 | -4.07 |
| 2023-02-28 | -0.90 |
| 2020-02-29 | -2.35 |
| 2019-02-28 | 0.53 |
| 2018-02-28 | 0.47 |
| 2017-02-28 | -0.20 |
| 2016-02-29 | 0.46 |
| 2015-02-28 | 0.46 |
| 2014-02-28 | 0.34 |
| 2013-02-28 | 1.54 |
| 2012-02-28 | 0.19 |
| 2011-02-28 | -0.12 |
| 2010-02-28 | -0.43 |
| 2009-02-28 | -2.01 |
| 2008-03-01 | -3.52 |
| 2007-03-03 | -1.34 |
| 2006-02-28 | 0.64 |
| 2005-02-28 | 0.38 |
| 2004-02-28 | 0.39 |
| 2003-03-01 | 0.35 |
| 2002-02-28 | 0.33 |
| 2001-03-03 | 0.39 |
| 2000-02-26 | -0.12 |
| 1999-02-27 | -0.12 |
| 1998-02-28 | -0.23 |
| 1997-03-01 | 0.05 |
